Metacrine MTCR shares are trading higher on Monday after multiple firms initiated coverage on the stock with a bullish rating.
Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases.
Metacrine shares traded up 6.83% to $10.86 on Monday at the time of publication. The stock has a 52-week high of $16.19 and a 52-week low of $9.06.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.